Quản lý Lipid

Apolipoprotein C-III Inhibition and the Atherosclerosis Paradox: Lessons from the Essence-TIMI 73b Olezarsen Study

The Essence-TIMI 73b trial reveals that despite a 64% reduction in triglycerides and a 72% drop in remnant cholesterol via olezarsen, non-calcified coronary plaque volume remained unchanged over 12 months.

Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management